Antineoplastics
1
Reactions 1481, p7-8 - 7 Dec 2013 S Antineoplastics Various toxicities: case report A 44-year-old woman developed various toxicities while receiving chemotherapy for plasmablastic lymphoma [routes, dosages, durations of treatment to reactions onset and outcomes not stated]. The woman, who had a history of chronic hepatitis C, alcoholism and IV drug abuse, was diagnosed with plasmablastic lymphoma. She received 8 cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP); this treatment was associated with grade 1 diarrhoea and grade 2 anaemia and neutropenia. Due to disease progression, she began receiving salvage therapy with ifosfamide, etoposide and carboplatin (ICE). However, treatment was discontinued after the third cycle due to treatment-related grade 3 haematological and renal toxicities. Despite treatment with bortezomib, her disease progressed and she died 26 months after her initial diagnosis. Author comment: "Overall, CHOP was well tolerated with grade 1 diarrhea and grade 2 anemia and neutropenia. . . [ICE] treatment was stopped after the 3rd cycle due to treatment-related grade 3 hematological and renal toxicities." Saba NS, et al. Bortezomib in plasmablastic lymphoma: A case report and review of the literature. Onkologie 36: 287-291, No. 5, May 2013. Available from: URL: http://dx.doi.org/10.1159/000350325 - USA 803096813 1 Reactions 7 Dec 2013 No. 1481 0114-9954/13/1481-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1481, p7-8 - 7 Dec 2013
SAntineoplastics
Various toxicities: case reportA 44-year-old woman developed various toxicities while
receiving chemotherapy for plasmablastic lymphoma [routes,dosages, durations of treatment to reactions onset andoutcomes not stated].
The woman, who had a history of chronic hepatitis C,alcoholism and IV drug abuse, was diagnosed withplasmablastic lymphoma. She received 8 cycles ofchemotherapy with cyclophosphamide, doxorubicin,vincristine and prednisone (CHOP); this treatment wasassociated with grade 1 diarrhoea and grade 2 anaemia andneutropenia. Due to disease progression, she began receivingsalvage therapy with ifosfamide, etoposide and carboplatin(ICE). However, treatment was discontinued after the thirdcycle due to treatment-related grade 3 haematological andrenal toxicities. Despite treatment with bortezomib, herdisease progressed and she died 26 months after her initialdiagnosis.
Author comment: "Overall, CHOP was well tolerated withgrade 1 diarrhea and grade 2 anemia andneutropenia. . . [ICE] treatment was stopped after the 3rdcycle due to treatment-related grade 3 hematological andrenal toxicities."Saba NS, et al. Bortezomib in plasmablastic lymphoma: A case report and reviewof the literature. Onkologie 36: 287-291, No. 5, May 2013. Available from: URL:http://dx.doi.org/10.1159/000350325 - USA 803096813
1
Reactions 7 Dec 2013 No. 14810114-9954/13/1481-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
